The HER2 therapy market is projected to grow from USD 16.8 billion in 2026 to USD 38.7 billion by 2036, registering a CAGR of 8.7%, according to Future Market Insights. The market is gaining momentum as advances in biomarker testing expand treatment eligibility and pharmaceutical companies develop targeted therapies for HER2-positive, HER2-low, and HER2-ultralow cancers.

The market is expected to add approximately USD 21.9 billion in absolute value between 2026 and 2036. Monoclonal antibodies are projected to remain the leading drug class, while HER2-positive breast cancer represents the dominant indication and injectable therapies account for the largest route of administration.

Get Access of Research Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-34934

HER2-Targeted Therapies Expand Across Broader Patient Populations

HER2-targeted treatment is becoming increasingly relevant as biomarker classification expands beyond traditional HER2-positive disease. The identification of HER2-low and HER2-ultralow tumors is creating additional treatment opportunities for patients who previously would not have been considered eligible for certain HER2-directed therapies.

Regulatory developments are also influencing the market. In January 2025, the FDA expanded trastuzumab deruxtecan for HER2-low and HER2-ultralow breast cancer using an approved diagnostic assay, increasing the importance of companion diagnostics and validated biomarker testing in treatment selection.

Future Market Insights is a market research company that provides market intelligence on global industries, including market sizing, forecasts, segmentation, competitive analysis, and regional trends.

The expansion of biomarker-defined patient populations is strengthening the connection between pathology laboratories, companion diagnostics, and targeted oncology treatment. Consistent HER2 assessment and breast cancer subtyping are becoming increasingly important components of treatment decision-making.

Monoclonal Antibodies Lead the Drug Class Segment

Monoclonal antibodies are projected to account for 42.0% of drug class demand in 2026, making them the leading category.

Established therapies such as trastuzumab and pertuzumab continue to form important components of HER2-targeted treatment strategies. Their use across different stages of HER2-positive disease supports recurring demand for antibody-based therapies.

The drug class is also evolving as pharmaceutical companies investigate new combinations, sequencing strategies, and approaches designed to address treatment resistance. These developments could broaden the role of antibody-based therapies across earlier and advanced disease settings.

HER2-Positive Breast Cancer Dominates the Indication Segment

HER2-positive breast cancer is projected to account for 61.0% of the indication segment in 2026.

The leading position of HER2-positive breast cancer reflects the established use of targeted therapies across early-stage and metastatic disease. Biomarker-guided treatment has become an important component of breast cancer management, creating sustained demand for HER2-directed therapies.

Expansion into HER2-low and HER2-ultralow disease is additionally broadening the potential patient population. As diagnostic classification becomes more precise, treatment decisions increasingly depend on validated laboratory testing and consistent reporting.

Injectable Therapies Lead the Route of Administration

Injectable therapies are projected to represent 74.0% of route-of-administration demand in 2026.

The strong position of injectable therapies is linked to the administration requirements of established monoclonal antibodies and antibody-drug conjugates. Many of these treatments are administered under clinical supervision, supporting demand across hospitals and specialized oncology centers.

Healthcare providers must manage infusion-related requirements, treatment monitoring, and patient follow-up alongside drug administration. These operational considerations contribute to the continued importance of healthcare facilities in HER2 therapy delivery.

Companion Diagnostics Become More Important to Treatment Selection

The expansion of HER2-defined treatment categories is increasing the importance of companion diagnostics. Validated assays can help identify patients whose tumors meet the biomarker criteria for specific therapies.

Hospital pathology laboratories therefore play an increasingly important role in HER2 testing, specimen evaluation, and reporting. Consistency in testing and interpretation is particularly important as treatment eligibility expands to lower levels of HER2 expression.

The growing connection between diagnostic testing and targeted oncology is expected to create opportunities for diagnostic developers, pathology laboratories, and healthcare providers.

Treatment Resistance Remains a Major Clinical Challenge

Treatment resistance remains one of the key challenges facing the HER2 therapy market. Patients can develop resistance to targeted therapies through biological mechanisms that reduce treatment effectiveness, creating demand for alternative treatment sequences and combination approaches.

Pharmaceutical companies are investigating next-generation antibody-drug conjugates, targeted combinations, and other therapeutic strategies to address resistant disease.

Clinical management can also become more complex as patients receive multiple lines of therapy. Monitoring requirements, treatment sequencing, and management of therapy-related adverse events can increase the workload for oncology teams.

Reimbursement Differences Can Influence Market Access

Regulatory approval does not always translate directly into uniform clinical adoption. Reimbursement authorities can apply different evidence requirements, cost-effectiveness thresholds, and funding policies when evaluating HER2 therapies.

These differences can create variations in patient access across countries. Healthcare systems may also assess the value of therapies differently depending on disease stage, biomarker category, treatment alternatives, and available clinical evidence.

As HER2-directed treatments expand into new biomarker-defined populations, reimbursement decisions are expected to remain an important factor shaping commercial uptake.

Pulmonary Monitoring and Treatment Management Add Clinical Complexity

Some HER2-targeted therapies require careful monitoring for treatment-related complications, including pulmonary adverse events associated with certain antibody-drug conjugates.

The need for appropriate patient selection, monitoring, and follow-up can influence treatment pathways and healthcare resource utilization. Oncology centers therefore require protocols that integrate biomarker confirmation, therapy administration, adverse-event monitoring, and ongoing assessment.

These requirements create opportunities for healthcare providers to strengthen multidisciplinary oncology care and treatment monitoring capabilities.

Access Full Report: https://www.futuremarketinsights.com/reports/her2-therapy-market

Competitive Landscape

The HER2 therapy market includes major pharmaceutical companies with established oncology portfolios and emerging biotechnology developers. Key players identified by Future Market Insights include Roche Holding AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Pfizer Inc., Merck & Co., Inc., Amgen Inc., Zymeworks Inc., and Jazz Pharmaceuticals plc.

Competition is centered on treatment efficacy, biomarker-defined eligibility, safety profiles, resistance management, therapeutic sequencing, and differentiation across HER2-positive and HER2-low populations.

Antibody-drug conjugates and next-generation targeted therapies are important areas of competitive development. Companies are also strengthening diagnostic and treatment strategies designed to identify patients most likely to benefit from specific HER2-directed therapies.

Future Outlook

The HER2 therapy market is forecast to reach USD 38.7 billion by 2036, rising from USD 16.8 billion in 2026. The market is expected to expand at an 8.7% CAGR, adding approximately USD 21.9 billion in absolute value during the forecast period.

Monoclonal antibodies are projected to maintain their leading position with a 42.0% share of drug class demand in 2026, while HER2-positive breast cancer is expected to command 61.0% of the indication segment. Injectable therapies are projected to account for 74.0% of route-of-administration demand.

Broader biomarker-based eligibility, expansion into HER2-low and HER2-ultralow disease, companion diagnostic adoption, and continued development of targeted therapies are expected to drive market growth. At the same time, treatment resistance, pulmonary monitoring requirements, reimbursement differences, and unequal access may influence the pace of adoption across healthcare systems.

Why FMI: https://www.futuremarketinsights.com/why-fmi

Related Reports:

·         https://www.openpr.com/news/4620360/dental-x-ray-systems-market-outlook-next-generation-imaging

·         https://www.openpr.com/news/4620364/handheld-dental-x-ray-systems-market-gains-momentum-as-wireless

·         https://www.openpr.com/news/4620367/dental-operatory-products-market-set-to-reach-usd-9-77-billion

Contact Us:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware - 19713, USA

T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.